Bellevue Group’s Arbutus Biopharma ABUS Stock Holding History

Bellevue Group’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-125,000	Closed	-$516K	–	125
2016 Q1	$516K	Buy	+125,000	New	+$447K	0.09%	111

Other funds holding ABUS

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SCM

Suffolk Capital Management New York $521M AUM 9.79% 1-Year Est. Return

Bellevue Group's ABUS Position: Q2 2016 in Review

Bellevue Group sold out of Arbutus Biopharma (ABUS) in Q2 2016, closing a stake of 125,000 shares — an estimated $516K sold.

Bellevue Group first reported a position in ABUS in Q1 2016 and held it in 1 quarter. The position peaked at $516K in Q1 2016. 51 funds tracked by Wall St. Rank hold ABUS as of Q2 2016.

Bellevue Group reported no remaining Arbutus Biopharma position as of Q2 2016 after selling out during the quarter.
Bellevue Group sold 125,000 Arbutus Biopharma shares in Q2 2016, an estimated $516K.
Bellevue Group first reported a position in Arbutus Biopharma in Q1 2016 and held it in 1 quarter.
Bellevue Group's Arbutus Biopharma position peaked at $516K in Q1 2016.
51 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2016.

Based on Bellevue Group's 13F filing for Q2 2016, filed 12 Aug 2016.